TREM2 and ovarian cancer: Given the intratumoral heterogeneity of TAM polarization in ovarian cancer, a strategic combination of macrophage-targeted therapies, such as CSF1R and TREM2 inhibitors, with immunotherapies holds promise for improving clinical outcomes.